Genenta Science is a gene therapy company which develops technologies for treating tumours. The therapeutic approach is based on the engineering of autologous hematopoietic stem cells to express a specific anti-tumour protein to tumour-infiltrating monocytes/macrophages. An HIV-derived and genetically modified viral vector – Lentivirus – is used as the vehicle for delivering the gene into the hematopoietic stem cells.